|Bid||1.6800 x N/A|
|Ask||1.7000 x N/A|
|Day's Range||1.6800 - 1.7500|
|52 Week Range||0.6500 - 1.8200|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Ottawa, Ontario--(Newsfile Corp. - January 18, 2021) - KWESST Micro Systems Inc. (TSXV: KWE) ("KWESST" or "the Company") today announced it has entered into a technology purchase agreement (the "Purchase Agreement") with DEFSEC Corporation ("DEFSEC") to acquire a proprietary non-lethal munitions technology system referred to as the Low Energy Cartridge technology ("LEC Technology"). The LEC Technology is a proprietary non-lethal cartridge-based ordnance system. DEFSEC is an Ottawa-based based private company owned by David Luxton ...
BAVENCIO is the first and only maintenance therapy for unresectable locally advanced or metastatic urothelial carcinoma (UC) approved by Health CanadaMISSISSAUGA, ON, Jan. 11, 2021 /CNW/ - EMD Serono Canada, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Canada ULC announced that Health Canada has approved BAVENCIO® (avelumab) for the maintenance treatment of patients with unresectable locally advanced or metastatic UC whose disease has not progressed following first-line platinum-based chemotherapy.
Ottawa, Ontario--(Newsfile Corp. - December 30, 2020) - KWESST Micro Systems Inc. (TSXV: KWE) ("KWESST" or "the Company") announced today that the U.S. Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for a second patent covering KWESST's "Phantom" electronic decoy system. KWESST previously announced on October 5th, 2020 the allowance of a first patent covering fifteen claims for a programmable multi-waveform radiofrequency generator capable of broadcasting and emulating all relevant military ...